[{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Juvise Pharmaceuticals \/ AbbVie"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bismuth Potassium Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Bismuth Potassium Citrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.

                          Brand Name : Pylera-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 10, 2023

                          Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.

                          Brand Name : Pylera

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 05, 2022

                          Lead Product(s) : Bismuth Potassium Citrate,Metronidazole,Tetracycline

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : AbbVie Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank